Organic compounds

14 - Alpha Demethylase Inhibitors Pipeline Research Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 8, 2021
Health, Pharmaceutical, Chemical compounds, Aromatic compounds, Organic compounds, Chloroarenes, Pipeline, Dioxolanes, Tertiary alcohols, Imidazoles, Orphan drugs

The "14 - Alpha Demethylase Inhibitors - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "14 - Alpha Demethylase Inhibitors - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This "14-alpha demethylase inhibitors - Pipeline Insight, 2021" report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in 14-alpha demethylase inhibitors pipeline landscape.
  • This segment of the report provides insights about the different 14-alpha demethylase inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
    There are approx.
  • 14-alpha demethylase inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

DGAP-News: AiCuris starts its first pivotal clinical phase 3 trial with pritelivir for the treatment of HSV infections in immunocompromised subjects based on efficacy and safety data from a phase 2 trial

Retrieved on: 
Thursday, July 8, 2021
Chemical compounds, Purines, Organic compounds, Foscarnet, Aciclovir, Chemistry, pritelivir, HSV, AiCuris Anti-infective Cures AG, PRITELIVIR, HSV, AICURIS ANTI-INFECTIVE CURES AG

The PRIOH-1 multi-center open label trial is designed to evaluate the efficacy and safety of orally administered pritelivir for the treatment of acyclovir-resistant mucocutaneous HSV infections in immunocompromised patients.

Key Points: 
  • The PRIOH-1 multi-center open label trial is designed to evaluate the efficacy and safety of orally administered pritelivir for the treatment of acyclovir-resistant mucocutaneous HSV infections in immunocompromised patients.
  • Efficacy was also seen in patients who in addition showed resistance or intolerance to foscarnet and had very limited treatment options.
  • In none of the patients, treatment with pritelivir was prematurely discontinued due to adverse events during the trial.
  • Based on the results from the recent US clinical phase 2 trial, AiCuris has started a pivotal phase 3 trial as a basis for NDA submission.

Biochem Launches Biochem® TEST: A Natural Testosterone Booster

Retrieved on: 
Wednesday, July 7, 2021
Hormones, Organic compounds, Chemical compounds, Androstanes, Testosterone, Enones, Estrogens, GABAA receptor positive allosteric modulators

NEW YORK, July 7, 2021 /PRNewswire/ -- Biochem , a company founded on the principles of delivering products rooted in Science by Nature, introduces Biochem TEST, a natural testosterone booster.

Key Points: 
  • NEW YORK, July 7, 2021 /PRNewswire/ -- Biochem , a company founded on the principles of delivering products rooted in Science by Nature, introduces Biochem TEST, a natural testosterone booster.
  • Specifically formulated with vitamins, plus natural herbs, TEST helps men feel their best both inside and outside of the bedroom.
  • "Testosterone is a key male sex hormone produced by the human body.
  • Unfortunately, after age 30, most men begin to experience a gradual decline in free testosterone.

Antares Pharma to Present at the Ladenburg Thalmann Annual Healthcare Conference

Retrieved on: 
Wednesday, July 7, 2021
Steroids, Organic compounds, Chemical compounds, Androstanes, Ketones, Testosterone enanthate, Teva Pharmaceuticals, Testosterone, Sumatriptan, Ladenburg Thalmann, Pharma

EWING, N.J., July 07, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the Company), a specialty pharmaceutical company, today announced that Robert F. Apple, President and Chief Executive Officer, is scheduled to present at the Ladenburg Thalmann Annual Healthcare Conference.

Key Points: 
  • EWING, N.J., July 07, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the Company), a specialty pharmaceutical company, today announced that Robert F. Apple, President and Chief Executive Officer, is scheduled to present at the Ladenburg Thalmann Annual Healthcare Conference.
  • Details of the presentation are as follows:
    A live webcast of the presentation will be available under the For Investors section of the Antares Pharma website at www.antarespharma.com.
  • Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of pharmaceutical products and technologies that address unmet needs in targeted therapeutic areas such as urology and endocrinology.
  • Antares Pharmas FDA-approved products include XYOSTED (testosterone enanthate) injection, OTREXUP (methotrexate) injection for subcutaneous use and Sumatriptan Injection USP, which is distributed by Teva.

Dipeptidyl Peptidase 4 Inhibitors Pipeline Research Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 7, 2021
Health, Diabetes, Proteases, Dipeptidyl peptidase-4 inhibitors, Dipeptidyl peptidase, Nitriles, Chemistry, Organic compounds, Chemical compounds, Tertiary alcohols, Piperidines, Dipeptidyl-peptidase IV family, Vildagliptin

The "Dipeptidyl Peptidase 4 Inhibitors - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Dipeptidyl Peptidase 4 Inhibitors - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This "Dipeptidyl peptidase 4 inhibitors - Pipeline Insight, 2021" report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Dipeptidyl peptidase 4 inhibitors pipeline landscape.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Dipeptidyl peptidase 4 inhibitors R&D.
  • Dipeptidyl peptidase 4 inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Global $14.4 Billion Recycled Polyethylene Terephthalate (rPET) Markets to 2028

Retrieved on: 
Wednesday, July 7, 2021
Materials, Organic polymers, Organic compounds, Plastics, Commodity chemicals, Polyolefins, Thermoplastics, Packaging materials, RPET, Polyethylene terephthalate, High-density polyethylene, Low-density polyethylene

The global recycled polyethylene terephthalate market size is expected to reach USD 14.40 billion by 2028, growing at a CAGR of 6.7%.

Key Points: 
  • The global recycled polyethylene terephthalate market size is expected to reach USD 14.40 billion by 2028, growing at a CAGR of 6.7%.
  • Recycled PET is a synthetic compound prepared from used PET products, which finds application in a wide range of end-use industries.
  • The global market was valued at USD 8.6 billion in 2020 and is estimated to grow at a CAGR of 6.7% from 2021 to 2028.
  • Chapter 3 Recycled Polyethylene Terephthalate (rPET) Market Variables, Trends, and Scope

Open Book Extracts Announces New Senior Executives To Drive Global Sales Strategy and Sales Operations

Retrieved on: 
Wednesday, July 7, 2021
Organic compounds, Chemical compounds, Chemistry, OBX, Vitamin C

Previously, she was Vice President of Sales at Prinova, one of the largest global ingredient distributors, and International Vitamin Corporation, global manufacturer and distributor of vitamins and related health products.

Key Points: 
  • Previously, she was Vice President of Sales at Prinova, one of the largest global ingredient distributors, and International Vitamin Corporation, global manufacturer and distributor of vitamins and related health products.
  • Over the course of my career, Ive had the opportunity to scale a number of global sales organizations, said Nicole Lemus, OBX Chief Revenue Officer at OBX.
  • Groncy most recently served as Senior Director of Sales and Project Management at Vit-Best Nutrition, and has held senior leadership roles at Bettera Brands and International Vitamin Corporation.
  • Jones brings almost a decade of strategy, operations, and technical sales expertise in the cannabis industry to the team at OBX.

Opiant Pharmaceuticals Announces Positive Top-line Results of Confirmatory Pharmacokinetic (PK) Study for OPNT003, Nasal Nalmefene, a Novel Investigational Treatment for Opioid Overdose

Retrieved on: 
Tuesday, July 6, 2021
Psychoactive drugs, Drugs, Organic compounds, Morphinans, Tertiary alcohols, Opioid antagonists, Ketones, Phenols, Naloxone, Nalmefene, Opioid, Addiction

SANTA MONICA, Calif., July 06, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc.(Opiant) (NASDAQ: OPNT) today announced positive top-line results from its confirmatory pharmacokinetic (PK) study for OPNT003, nasal nalmefene, for opioid overdose.

Key Points: 
  • SANTA MONICA, Calif., July 06, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc.(Opiant) (NASDAQ: OPNT) today announced positive top-line results from its confirmatory pharmacokinetic (PK) study for OPNT003, nasal nalmefene, for opioid overdose.
  • We are very pleased with the results of this confirmatory PK study.
  • Importantly, the data are consistent with the findings of our initial pilot study, said Roger Crystal, M.D., CEO and President, of Opiant.
  • Opiant Pharmaceuticals, Inc., the company that developed NARCAN Nasal Spray, is building a leadingfranchiseof new medicines to combat addictions and drug overdose.

Global Recycled Polyethylene Terephthalate (rPET) Markets 2021-2028 by Product (Clear, Colored), & End Use (Fiber, Food & Beverage Containers & Bottles) - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 6, 2021
Packaging, Chemicals, Plastics, Manufacturing, Organic polymers, Plastics, Materials, Organic compounds, Polyolefins, Polymers, Thermoplastics, Containers, Polyethylene terephthalate, Plastic bottle, Recycling, High-density polyethylene

The global recycled polyethylene terephthalate market size is expected to reach USD 14.40 billion by 2028, growing at a CAGR of 6.7%.

Key Points: 
  • The global recycled polyethylene terephthalate market size is expected to reach USD 14.40 billion by 2028, growing at a CAGR of 6.7%.
  • Recycled PET is a synthetic compound prepared from used PET products, which finds application in a wide range of end-use industries.
  • The resins are produced from post-consumer PET bottle flakes and are one of the most stable forms of recycled PET.
  • The food & beverage containers & bottles end-use segment is projected to register the fastest CAGR over the forecast period.

Chronic Lymphocytic Leukemia (CLL) Clinical Landscape Research Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 6, 2021
Health, Oncology, Cancer, Leukemia, Chemical compounds, Organic compounds, Chronic lymphocytic leukemia, CLL, Ibrutinib, Lymphoid leukemia, Monoclonal B-cell lymphocytosis, Indolent lymphoma

The "Chronic Lymphocytic Leukemia (CLL)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Chronic Lymphocytic Leukemia (CLL)" report has been added to ResearchAndMarkets.com's offering.
  • Chronic lymphocytic leukemia (CLL) is a disorder where the bone marrow produces B lymphocytes that are morphologically mature but immunologically less mature.
  • The publisher estimates that in 2018, there were 86,900 incident cases of chronic lymphocytic leukemia (CLL) worldwide, and expects that number to increase to 91,000 incident cases by 2027.
  • In March 2021, Johnson & Johnson and Zydus entered into a confidential settlement agreement that likely delays the launch of generic Imbruvica.